DV
Dividend Vision

BBC — Virtus LifeSci Biotech Clinical Trials ETF

Virtus LifeSci Biotech Clinical Trials ETF (BBC)

BBC pays a 1.24% distribution rate, annual, on a 0.65% expense ratio. Its Distribution Safety Score™ is 50 (Caution). Total return is 107.4% over the past 11.7 years, 260.9 points behind SPY at 368.3%. Its deepest 1-year drawdown was 15.1%.

Virtus LifeSci Biotech Clinical Trials ETF tracks an index of U.S. biotechnology companies whose lead drugs are in Phase 1, Phase 2, or Phase 3 clinical trials, prior to receiving marketing approval. The fund carries a modest current distribution rate with annual distributions and an expense ratio of 0.65%. This fund appeals to investors seeking exposure to early-stage biotech development companies, though it carries the higher risk typical of clinical-stage pharmaceutical investments.

BBC key facts

Distribution Safety Score™
50 · Caution
Issuer
Virtus Investment Partners
Asset type
ETF
Asset class
Equity
Inception date
12/16/2014
Expense ratio
0.65%
Distribution rate
1.24%
Distribution frequency
Annual
Trailing yield
1.24%
Last close
$52.87
AUM
$40,819,699
Average volume
9700.0
Last dividend
$0.6550
Ex-dividend date
12/22/2025
Payment date
12/29/2025
Beta
1.23